Epigenica Unveils Breakthrough Epigenetics Platform, Launches First Commercial ChIP-seq Kit for High-throughput, Multiplex Genome-wide Profiling
Epigenica Unveils Breakthrough Epigenetics Platform, Launches First Commercial ChIP-seq Kit for High-throughput, Multiplex Genome-wide Profiling
Almi Invest has made a significant investment in the company Epigenica early in the fall. The company is focused on advancing epigenomics by delivering state-of-the-art epigenetic screening tools. With its multiplexing technology, the company offers its customers more comprehensive information faster, at a fraction of the cost they currently pay for the same knowledge.
Epigenica attended the AI for Health Summit in Paris on November 22. At our booth, shared with EIT Health, we engaged in enlightening conversations with many attendees, fostering a vibrant exchange of ideas.
Epigenica announces the appointment of board members Anders Nordström, Eva Walde, Stina Wallmark and Professor Yang Shi.
Epigenica has become one of five Swedish start-ups selected to accelerate on the French Precision health market.
Epigenica has during October closed a successful investment round of an undisclosed amount, positioning the company for product launch.
We are really looking forward to the coming period, bringing the launch of our first product to an exciting and important market, says Mohamad Takwa, CEO of Epigenica.
Our CEO Mohamad Takwa presented Epigenica’s latest developments during the KI InvestorDay.
Epigenica has emerged as one of the standout companies among the health tech programs of Tech Tour 2022.
Epigenica’s CEO and co-founder Mohamad Takwa was invited to take part in a round table discussion about personalized and precision health.
Epigenica’s CSO and co-founder Simon Elsässer was interviewed by Swedish TV4 to help viewers better understand click chemistry and the implications of this year’s winner of the Nobel Prize in Chemistry.
This website uses cookies. By continuing to use this site, you accept our use of cookies.
